Acta Pharmaceutica Sinica B · 2022 · 111 citations · 50 references
PharmacyOncologyPharmacologyDrug DeliveryNanoparticle Drug DeliveryTargeted Drug DeliveryBlood-brain Barrier DeliveryBlood-brain Barrier PenetrationCancer NanomedicineNanomaterials For Drug DeliveryNanomedicineNanoparticle DesignBlood-brain Barrier PermeabilityCancer-associated MacrophagesGlioma ChemotherapyNanoparticle-based ChemotherapyPeptide-modified BiomaterialsTumor Cell ProliferationTumor-targeted Drug DeliveryTumor-targeted Prodrugs
Glioma is a primary aggressive brain tumor with high recurrence rate. The poor efficiency of chemotherapeutic drugs crossing the blood‒brain barrier (BBB) is well-known as one of the main challenges for anti-glioma therapy. Moreover, massive infiltrated tumor-associated macrophages (TAMs) in glioma further thwart the drug efficacy. Herein, a therapeutic nanosystem (SPP-ARV-825) is constructed by incorporating the BRD4-degrading proteolytic targeting chimera (PROTAC) ARV-825 into the complex micelle (SPP) composed of substance P (SP) peptide-modified poly(ethylene glycol)-poly(d,l-lactic acid)(SP-PEG-PDLLA) and methoxy poly(ethylene glycol)-poly(d,l-lactic acid) (mPEG-PDLLA, PP), which could penetrate BBB and target brain tumor. Subsequently, released drug engenders antitumor effect via attenuating cells proliferation, inducing cells apoptosis and suppressing M2 macrophages polarization through the inhibition of IRF4 promoter transcription and phosphorylation of STAT6, STAT3 and AKT. Taken together, our work demonstrates the versatile role and therapeutic efficacy of SPP-ARV-825 micelle against glioma, which may provide a novel strategy for glioma therapy in future.
50
Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
Jing Lü, Yimin Qian, Martha Altieri et al. · Chemistry & Biology · 2015 · 1.1K citations · Full text